… different activity of pralatrexate in malignancies originating … in lymphoma has allowed dissecting
and revealing multiple … for the treatment of refractory cutaneous T-cell lymphoma (CTCL). …

… This drug shows potent anti-proliferative and HDAC inhibi… PTCL, the others being vorinostat
and pralatrexate [39]. This … relapsed or refractory peripheral T-cell lymphoma. Future Oncol., …

… of T-lymphocytes revealed that HBZ RNA promotes … promoter, we found that T-cell lymphomas
frequently developed. In these … , pralatrexate (now known as Folytn) became the first drug …

… After TCR-activation, Rac1 stimulates the creation of a new … co-engagement, and reveal
defects of T cell selection in the … T cell lymphoma (AITL), peripheral T cell lymphoma (PTCL)-…

… , or fatty acids in the same cells, generating up to 85% of the total … However, recent evidence
reveals a high glycolytic rate in … As for other cell types, mTOR plays a crucial role in T-cell …

… The annals of medicine reveal that the first antagonist given … generation 5 PAMAM
dendrimers conjugated to two distinct … sensitivity to adoptive T cell immunotherapy compared to …

… Pralatrexate was recently approved by the Food and Drug Administration for relapsed or
refractory peripheral T-cell … Pralatrexate shows impressive activity with minimal toxicity in …

… that ITK-SYK causes T-cell lymphomas in mice which mimic … negative before alloSCT and
acquired primary infection. All but … Conclusion: This study shows the successful generation of …

… Similarly pralatrexate (Fotolyn) is a novel targeted antifolate … 2009 for the treatment of peripheral
T-cell lymphoma (PTCL). 18 … revealed its potential in indolent non-Hodgkin's lymphoma (…

… of the combination of the epigenetic drugs 5′-azacytidine … Accordingly, acquired tagraxofusp
resistance was identified … in vivo via antigen-specific T-cell degranulation and robust IFN-γ …